Elizabeth C. Lieschke

Parkville, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Transcriptomic changes including p53 dysregulation prime DNMT3A mutant cells for transformation.

Transcriptomic changes including p53 dysregulation prime DNMT3A mutant cells for transformation.

Journal: EMBO reports

Published: November 22, 2024

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: Molecular cancer

Published: May 23, 2024

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

Journal: Therapeutic advances in medical oncology

Published: July 01, 2023

Mouse models to investigate in situ cell fate decisions induced by p53.

Mouse models to investigate in situ cell fate decisions induced by p53.

Journal: The EMBO journal

Published: June 19, 2023

Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.

Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.

Journal: Cancer discovery

Published: April 14, 2023

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: medRxiv : the preprint server for health sciences

Published: March 30, 2023

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

Journal: Cell death and differentiation

Published: February 24, 2023

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

Journal: Cell death and differentiation

Published: December 12, 2022

Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice.

Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice.

Journal: Cell death and differentiation

Published: November 11, 2022

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

Journal: Cancer research

Published: November 22, 2021

Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence.

Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence.

Journal: Cell death and differentiation

Published: September 28, 2021

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Journal: Cancer research

Published: March 09, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026